Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis

Xiong, Xingjiang; Wang, Pengqian; Su, Kelei; Cho, William C.; Xing, Yanwei

doi:10.1016/j.phrs.2020.105056

Cited by 126 publications

(152 citation statements)

References 24 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Our study found TCM as adjuvant therapy achieved signi cant lower mortality and OAE with higher cure rate, which is consistent with previous meta-analysis [14][15][16] . While use of traditional herbs remain controversial in clinical practice, the bene cial effect is biologically reasonable [39][40][41][42][43] .…”

Section: Discussionsupporting

confidence: 92%

Comparative Effectiveness and Safety of 32 Pharmacological Interventions Recommended by Guidelines for COVID-19: A Systematic Review and Network Meta-Analysis Combining 66 Trials

Zhou

Zeng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To evaluate comparative efficacy and safety of pharmacological interventions in patients with coronavirus disease 2019. Methods: Medline, Embase, the Cochrane Library and clinicaltrials.gov were searched for randomized controlled trials (RCTs) in patients infected with SARS-COV-2/SARS-COV. Random-effects network meta-analysis within Bayesian framework was performed, followed by Grading of Recommendations Assessment, Development and Evaluation (GRADE) system assessing quality of evidence. The primary outcome of interest includes mortality, cure, viral negative conversion (VNC) and overall adverse events (OAE). Odds ratio (OR) with 95% confidence interval (CI) was calculated as the measure of effect size.Results: 66 RCTs with 19,095 patients were included, involving standard care (SOC), 8 different antiviral agents, 6 different antibiotics, high and low dose chloroquine (CQ_HD, CQ_LD), traditional Chinese medicine (TCM), corticosteroids and other treatments. Compared with SOC, significant reduction of mortality was observed for TCM (OR=0.34, 95%CI: 0.20-0.56, moderate quality) and corticosteroids (OR=0.84, 0.75-0.96, low quality) with improved cure rate (OR=2.16, 1.60-2.91, low quality for TCM; OR=1.17, 1.05-1.30, low quality for corticosteroids). However, increased risk of mortality was found for CQ_HD versus SOC (OR=3.20, 1.18-8.73, low quality). TCM was associated with decreased risk of OAE (OR=0.52, 0.38-0.70, very low quality) but CQ_HD (OR=2.51, 1.20-5.24) and IFN (OR=2.69, 1.02-7.08) versus SOC with very low quality) were associated with an increased risk. Conclusions: Corticosteroids and TCM may reduce mortality and increase cure rate with no increased risk of OAEs compared with standard care. CQ_HD might increase the risk of mortality. CQ, IFN and other antiviral agents could increase the risk of OAEs. The current evidence is generally uncertain with low quality and further high-quality trials are needed.

show abstract

Section: Discussionsupporting

confidence: 92%

Comparative Effectiveness and Safety of 32 Pharmacological Interventions Recommended by Guidelines for COVID-19: A Systematic Review and Network Meta-Analysis Combining 66 Trials

Zhou

Zeng

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently, Xiong et al [ 1 ] published in a recent article in the journal a systematic review and meta-analysis based on 18 randomized controlled trials (RCTs) to evaluate the clinical evidence on Chinese herbal medicine (CHM) for the treatment of COVID-19. Their results demonstrated that compared with the western medicine group, CHM group had significant improvements in lung CT, clinical cure rate, length of hospital stay, clinical symptoms and so on.…”

mentioning

confidence: 99%

“…First, this meta-analysis claimed to include 18 RCTS, but some of the included studies were actually retrospective observational research (references 17, 18, 21–24, 27 in Xiong et al’s [ 1 ] study). RCT is a study design that randomly assigns participants into an experimental group or a control group.…”

mentioning

confidence: 99%

Chinese herbal medicine supplementation therapy on COVID-19

Zhang

2020

Pharmacological Research

View full text Add to dashboard Cite

“…Similar efforts for therapeutics innovation using traditional and herbal medicines have been made against the complex and diverse clinical findings of COVID-19 around the world, including in China (Xiong et al, 2020;Xu and Zhang, 2020). Such efforts to bridge traditional therapeutics folklore in local communities would benefit from deploying systems science concepts and multiomics technologies so as to build a strong evidence base and independent replication of the findings essential for progress in global science.…”

Section: Building a Systems Science Foundation For Precision Herbal Mmentioning

confidence: 99%

Turning Up the Volume for Precision Herbal Medicine in Africa in an Era of COVID-19 and Planetary Biodiversity Loss

Thomford

Yahaya

Ekor

et al. 2020

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

What would it take in terms of the structural reforms in science, technology, and culture to cultivate sustainable therapeutic and preventive medicine innovations against zoonotic infections such as coronavirus disease 2019 (COVID-19) in the 21st century? In May 2019, the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services warned that ''around one million animal and plant species are now threatened with extinction.'' Biodiversity is essential for drug discovery and development. We are currently facing a dual challenge in therapeutics innovation with COVID-19 and loss in planetary biodiversity. Hence, there is an urgent need for new ideas and strategies for drug discovery as well as repurposed drugs for the COVID-19 pandemic. To these ends, the existing scholarship in, and the field of precision herbal medicine provide an alternative source for discovery of novel therapeutics against the novel coronavirus. We propose that the application of precision herbal medicine in Africa could usefully contribute to current efforts for therapeutics innovation for the COVID-19 pandemic, and beyond. The pandemic calls for interdisciplinary dialogue and turning up the volume for precision herbal medicine in Africa, and importantly, in ways informed by robust systems science as well as broad public engagement to codesign medicines in the 21st century.

show abstract

Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis

Cited by 126 publications

References 24 publications

Comparative Effectiveness and Safety of 32 Pharmacological Interventions Recommended by Guidelines for COVID-19: A Systematic Review and Network Meta-Analysis Combining 66 Trials

Comparative Effectiveness and Safety of 32 Pharmacological Interventions Recommended by Guidelines for COVID-19: A Systematic Review and Network Meta-Analysis Combining 66 Trials

Chinese herbal medicine supplementation therapy on COVID-19

Turning Up the Volume for Precision Herbal Medicine in Africa in an Era of COVID-19 and Planetary Biodiversity Loss

Contact Info

Product

Resources

About